Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 5
Clinical study of ctDNA-based MRD detection and INTERCEPT program update
The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).
- Please describe some recent studies exploring the utility of ctDNA in CRC
- Dr Dasari: INTERCEPT program: ctDNA testing for MRD in CRC
- Association of positive ctDNA-based MRD assays during surveillance and undiagnosed concomitant radiographic recurrences CRC (Dasari, et al. ASCO 2023. Abstract 3522.)
- Results from a prospective real-world clinical cohort (Maddalena, et al. ASCO GI 2024. Abstract 27.)
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
